FRMM
ETHZilla Corporation
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$5.31
−4.15%0
Insider buys (3m)
5
Insider sells (3m)
-$1.6M
Net value (3m)
+5.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 14, 2026 | Rudisill McAndrew · director, officer: Chief Executive Officer | F-InKind | 98,174 | $5.16 |
| Aug 14, 2026 | Saunders John Tazewell · officer: Chief Financial Officer | F-InKind | 16,151 | $5.16 |
| Jul 23, 2026 | Lomashuk Konstantin · 10 percent owner | Sale | 250,000 | $6.00 |
| Jul 20, 2026 | Lomashuk Konstantin · 10 percent owner | Sale | 2,562 | $6.30 |
| Jul 14, 2026 | Lomashuk Konstantin · 10 percent owner | Sale | 3,387 | $6.15 |
| Jul 9, 2026 | Lomashuk Konstantin · 10 percent owner | Sale | 3,702 | $6.41 |
| Jul 9, 2026 | Lomashuk Konstantin · 10 percent owner | Sale | 1,100 | $6.13 |
| Apr 6, 2026 | Dalton Angela · director | A-Award | 203,562 | $0.00 |
| Apr 3, 2026 | Edwards Michael A · director | A-Award | 203,562 | $0.00 |
| Apr 3, 2026 | Heter Crystal Jane · director | A-Award | 241,918 | $0.00 |
| Apr 3, 2026 | New Jason Griffin · director | A-Award | 241,918 | $0.00 |
| Apr 3, 2026 | Rudisill McAndrew · director, officer: Chief Executive Officer | A-Award | 1,884,979 | $0.00 |
| Apr 3, 2026 | Saunders John Tazewell · officer: Chief Financial Officer | A-Award | 358,592 | $0.00 |
| Apr 3, 2026 | Smith Ryan Lewis · director | A-Award | 241,918 | $0.00 |
| Apr 3, 2026 | SUCKLING ANDREW P · director | A-Award | 241,918 | $0.00 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 14, 2026